Lee Seung-kyou, vice president of the Korea Biotechnology Industry Organization, addressed the Bio USA conference in San Diego, where the Korea Biotechnology Industry Organization, Korea Trade-Investment Promotion Agency, and the Trade Ministry launched the Korea Pavilion. The pavilion, which is the largest-ever operation of its kind, features 26 participating firms and two institutions. Over 1,000 industry officials affiliated with Korean firms are among the 20,000 global participants. Lee highlighted the growing importance of biosecurity and bio-sovereignty and the increasing attention on obesity treatments and AI-driven drug development in the biotechnology sector. Major industry players such as Samsung Biologics, Celltrion, Lotte Biologics, and SK Biopharmaceuticals showcased their capabilities at the conference, with Samsung Biologics emphasizing its commitment to sustainable management and development capabilities. At the conference, Lee Seung-kyou emphasized the increasing importance of biosecurity and bio-sovereignty, as well as the growing interest in obesity treatments and AI-driven drug development in the biotechnology sector. Major industry players, including Samsung Biologics, Celltrion, Lotte Biologics, and SK Biopharmaceuticals, showcased their capabilities, with Samsung Biologics highlighting its commitment to sustainable management and development capabilities. The Korea Pavilion, which was launched to support small to mid-sized firms in attracting new business partners, is the largest-ever operation of its kind, featuring 26 participating firms and two institutions. Moreover, the absence of Chinese firms at the event was noted, possibly due to the tensions between the US and China arising from the US Congress' BioSecure Act. Additionally, Celltrion reported a significant increase in industry officials visiting its booth, with plans to hold meetings with over 150 companies throughout the event.